News
-
-
-
-
PRESS RELEASE
Xenetic Biosciences, Inc. Presents Positive Data Demonstrating DNase I Significantly Improves Efficacy of Anti-CTLA-4 Immune Checkpoint Blockade in Preclinical Colorectal Carcinoma Models
Positive preclinical data on systemic DNase I combined with CTLA-4 antibody presented at SITC 2024, targeting NETs to enhance antitumor immunity and generate immunological memory in MSS/MMRp CRC tumors -
-
PRESS RELEASE
Xenetic Biosciences, Inc. Extends Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform
Xenetic Biosciences extends Research Funding and Option Agreement with The Scripps Research Institute to advance DNase-based oncology program, targeting cancer with NETs via systemic DNase and CAR T-cell therapies -
-
PRESS RELEASE
Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024
Xenetic Biosciences to present abstract at SITC 39th Annual Meeting on DNase I targeting Neutrophil Extracellular Traps for improved immune checkpoint blockade in CRC models -
-
PRESS RELEASE
Xenetic Biosciences, Inc. Enters into Materials Transfer Agreement with Tokyo Medical University for the Advancement of Its DNase-Based Oncology Platform
Xenetic partners with Tokyo Medical University to evaluate recombinant DNase I for Ewing sarcoma treatment in preclinical model. Agreement enhances DNase program development
